In some cancers, such as colorectal, bladder, breast cancers, the anti-cancer mechanism of CTNNA1 is well understood, which has been translated into clinical practice, such as screening CTNNA1 to guide the management of HDGC; however, in other cancers, such as endometrial, ovarian, and pancreatic cancers, the mechanism and related signaling pathway of CTNNA1 remain to be fully understood. This evidence concerns the gene CTNNA1 and breast carcinoma.